Going anti-Viral  By  cover art

Going anti-Viral

By: Going Anti-Viral
  • Summary

  • Introducing Going anti-Viral, the podcast of the IAS–USA, a professional continuing medical education organization focused on HIV and other viral diseases. I’m Dr Michael Saag, professor emeritus of medicine and infectious diseases at the University of Alabama at Birmingham and volunteer member of the IAS–USA Board of Directors.
    Join us as we interview experts in viral medicine about their area of specialty and current developments in the field. Other episodes are drawn from the IAS-USA vast catalogue of panel discussions, Dialogues, and various meetings and conferences.
    Going anti-Viral is a podcast series for clinicians, produced by the International Antiviral Society–USA. The IAS–USA is a not-for-profit professional organization committed to improving the treatment, care, and quality of life for people with or at risk for HIV or other viral infections and their complications through balanced education and information. This podcast is intended as a technical source of information for specialists in this field, but we hope anyone listening will enjoy learning more about the state of modern medicine around viral infections and their consequences.

    © 2024 Going anti-Viral
    Show more Show less
activate_primeday_promo_in_buybox_DT
Episodes
  • Episode 21 - New HIV Prevention: “What I’m Excited About” with Dr Raphael Landovitz
    Jul 16 2024

    In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Raphael Landovitz from the UCLA Medical School about the latest information on HIV prevention via Preexposure Prophylaxis, or PrEP. They discuss the history of PrEP and early efficacy and then move into a discussion of the evolution of PrEP from episodic dosing to longer-acting therapies. The episode also highlights recent research and how that may impact the future of PrEP dosing.

    0:00 - Introduction

    1:59 - History of Preexposure Prophylaxis, or PrEP

    5:39 - Why initial PrEP regimens were not 100% effective

    12:01 - Discussion of episodic PrEP and 2-1-1 regimens

    16:22 - How longer-acting therapy has been shown to be superior to episodic dosing

    20:29 - LEVI syndrome - what is it?

    25:05 - What the future holds for PrEP

    29:18 - Closing Remarks

    __________________________________________________

    Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

    Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

    Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

    Follow Going anti-Viral on:
    Apple Podcasts
    YouTube
    Instagram
    TikTok
    ...

    Show more Show less
    33 mins
  • Episode 20 - The Impact of GLP-1 Receptor Agonists with Dr Suman Srinivasa
    Jul 2 2024

    Episode 20 - The Impact of GLP-1 Receptor Agonists with Dr Suman Srinivasa


    In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Suman Srinivasa from Harvard Medical School about the impact of GLP-1 receptor agonists on diabetes and obesity. They discuss the mechanisms, benefits, and current and potential applications, including their use by people with HIV. The episode also highlights future prospects and challenges, including access to medication.


    00:00 Introduction


    01:42 Understanding GLP-1 Receptor Agonists


    03:19 Mechanisms and Benefits of GLP-1 Receptor Agonists


    05:34 Clinical Applications and Insurance Challenges


    09:56 GLP-1 Receptor Agonists in HIV Patients


    15:50 Future Prospects and Broader Applications


    23:37 Closing Remarks

    __________________________________________________

    Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

    Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

    Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

    Follow Going anti-Viral on:
    Apple Podcasts
    YouTube
    Instagram
    TikTok
    ...

    Show more Show less
    27 mins

What listeners say about Going anti-Viral

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.